Want to see TSE:DTC full AI Analyst Report?
DTC Stock Chart & Stats
C$0.78
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.78
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.37 - C$0.93
Previous CloseN/A
Volume0.00
Average Volume (3M)68.27K
Market Cap
C$28.42M
Enterprise ValueC$31.08
Total Cash (Recent Filing)C$2.95M
Total Debt (Recent Filing)C$1.56M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformDefence Therapeutics' Accum® platform is a durable, platform-level asset that targets intracellular delivery challenges across oncology and infectious disease programs. A validated platform can support multiple internal programs, attract licensing or partnerships, and compound value over years if clinical validation advances.
Positive Equity Position (TTM)Having positive shareholders' equity and rising total assets in the latest TTM provides a buffer against insolvency risk and supports continuity of operations. This reduces immediate bankruptcy risk, helps in negotiating future financings, and lengthens runway relative to peers with persistent negative equity.
Reduction In Reported Losses (2024→2025)Material improvement in annual losses indicates management succeeded in cost control or program re-prioritization. Sustained lower burn, if maintained, improves the company's ability to extend runway, reduces dilution pressure from capital raises, and supports a more stable development path over the next several quarters.
Bears Say
No Revenue; Recurring Net LossesThe company remains a pre-revenue biotech with recurring multi‑million dollar losses. Without product sales, progress depends on R&D milestones and financing. Continued losses mean sustained dilution or debt financing risk, limiting financial flexibility and raising execution risk for long-term program development.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow demonstrate ongoing cash burn tied to development activities. This structural cash consumption necessitates recurrent capital raises, diverts management to financing activities, and increases the probability of dilution or unfavorable financing terms over the medium term.
Balance-sheet Volatility & Debt ExposureHistoric swings into negative equity and a meaningful debt load create balance-sheet volatility and complicate leverage metrics. If losses recur, refinancing risk and covenant pressure could intensify, limiting strategic optionality and increasing the chance that financing becomes dilutive or restrictive over the coming quarters.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.36 and its highest was C$0.93 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$28.42M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 96 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -C$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―